Type 1 Diabetes TrialNet Clinical Network Hub

$1,425,304U01FY2014DKNIH

Benaroya Research Inst At Virginia Mason, Seattle WA

Investigators

Linked publications & trials

Paper 39670998 Paper 39167668 Paper 39103721 Paper 38712386 Paper 38621411 Paper 37940642 Paper 37000695 Paper 36920087 Paper 36326757 Paper 36175392 Paper 35998266 Paper 35880956 Paper 35524749 Paper 35041021 Paper 34853027 Paper 34806648 Paper 34642772 Paper 34551936 Paper 34127860 Paper 33658358 Paper 33496819 Paper 33441381 Paper 33424774 Paper 33277338 Paper 32833543 Paper 32789003 Paper 32669415 Paper 32573495 Paper 32502242 Paper 32457058 Paper 32404353 Paper 32019856 Paper 32003110 Paper 31982961 Paper 31937610 Paper 31867614 Paper 31768570 Paper 31558546 Paper 31180194 Paper 31167877 Paper 30967424 Paper 30894366 Paper 30891858 Paper 30830871 Paper 30830868 Paper 30730939 Paper 30709843 Paper 30629603 Paper 30552130 Paper 30405601 Paper 30275285 Paper 30232284 Paper 30167735 Paper 30089716 Paper 30012675 Paper 29931415 Paper 29925930 Paper 29851415 Paper 29769238 Paper 29171129 Paper 29164254 Paper 29040630 Paper 29025879 Paper 28860125 Paper 28770323 Paper 28707353 Paper 28531305 Paper 28500393 Paper 27704166 Paper 19940299

Abstract

DESCRIPTION (provided by applicant): Diabetes TrialNet is an international clinical trial network aimed to delay or prevent the onset of type 1 diabetes. As described, the new Diabetes TrialNet structure will now include a Diabetes TrialNet Clinical Hub, the Director of which will be part of the TrialNet leadership team including representatives of the NIH, the TrialNet Coordinating Center, and TrialNet chairman. The Benaroya Research Institute (BRI) serves as a nexus of T1D research, and with decades of clinical trial experience in T1D prediction and prevention, Dr. Greenbaum is uniquely qualified to serve as the TrialNet Clinical Network Hub (HUB). This application describes our proposal to become the Diabetes TrialNet Clinical HUB. We focus on three areas; activities to (a) enhance risk screening and prevention trial recruitment, (b) support clinical trials, and (c) enhance clinical administration and include proposed pilot studies to test innovative ideas for increasing recruitment, retention, and cost efficiencies.

View original record on NIH RePORTER →